baber/WOPTO huggingface dataset:
Patent JP-H0645633-B2 (JP)
IPC: C07F9/6578
Filed: 1985-02-15
Abstract: Transition metal-diorganophosphite complex catalyzed carbonylation processes, especially hydroformylation, as well as transition metal-diorganophosphite ligand complex compositions, diorganophosphite ligands and transition metal-diorganophosphite catalysts.
Patent JP-2860604-B2 (JP)
IPC: A61K31/495
Filed: 1995-04-24
Granted: 1999-02-24
Abstract: This invention relates to novel, pharmaceutically active benzimidazolone derivatives of formula (I), wherein the dashed line, R<0> through R<6> and X<1> through X<3> are defined as in the specification. These compounds exhibit central dopaminergic activity and are useful in the treatment of CNS disorders.
Patent JP-H0431708-B2 (JP)
IPC: A61L2/14
Filed: 1988-02-24
Abstract: A process for dry sterilization of medical devices and materials in which these materials are subjected to an electrical discharge in a gaseous atmosphere to produce an active plasma for surface sterilization of the devices and materials. <IMAGE>
Patent JP-4184435-B2 (JP)
IPC: A61K31/231
Filed: 1997-06-26
Granted: 2008-11-19
Abstract: Inhibitors of oleamide hydrolase, responsible for the hydrolysis of an endogenous sleep-inducing lipid (1, cis-9-octadecenamide) were designed and synthesized. The most potent inhibitors possess an electrophilic carbonyl group capable of reversibly forming a (thio) hemiacetal or (thio) hemiketal to mimic the transition state of a serine or cysteine protease catalyzed reaction. In particular, the tight binding  alpha -keto ethyl ester 8 (1.4 nM) and the trifluoromethyl ketone inhibitor 12 (1.2 nM) were found to have exceptional inhibitory activity. In addition to the inhibitory activity, some of the inhibitors displayed agonist activity which resulted in the induction of sleep in laboratory animals.
Patent JP-3236022-B2 (JP)
IPC: C07C215/14
Filed: 1992-08-21
Granted: 2001-12-04
Abstract: PCT No. PCT/EP92/01924 Sec. 371 Date Feb. 18, 1994 Sec. 102(e) Date Feb. 18, 1994 PCT Filed Aug. 21, 1992 PCT Pub. No. WO93/04148 PCT Pub. Date Mar. 4, 1993.A novel compound comprises a chemical compound comprising or including a cyclic ring system such as an aromatic ring system, the compound carrying at least two substituents of the general formula (I) below on the ring system -A-NR1R2 (I) where A is an aliphatic hydrocarbyl group that is optionally interrupted by one or more hetero atoms and that is straight chain or branched, and R1 and R2 are the same or different and each is independently a hydrocarbyl group containing 9 to 40 carbon atoms, optionally interrupted by one or more hetero atoms, the substituents being the same or different and the compound optionally being in the form of a salt thereof. Such compounds may be used as additives for improving the cold flow properties of crude oil, lubricating oil or fuel oil.
Patent JP-H0416281-B2 (JP)
IPC: B23B29/034
Filed: 1986-08-23
Abstract: PCT No. PCT/DE86/00339 Sec. 371 Date Apr. 28, 1987 Sec. 102(e) Date Apr. 28, 1987 PCT Filed Aug. 23, 1986 PCT Pub. No. WO87/01319 PCT Pub. Date Mar. 12, 1987.A tool for metal-cutting comprises a holder (3) on which is mounted in its front part (3a) a cutting plate (6) and which is formed together with a base body (2) as an integral unit by being connected rigidly to the base body (2) in the region of its rear end (3b), a perforation (9) in the holder forming a parallel-type spring arrangement so that the holder is resiliently deflectable relative to a support (11) formed by the base body (2), and an adjustment device for deflecting the holder in use as desired.
Patent JP-3219408-B2 (JP)
IPC: C07C307/02
Filed: 1992-08-28
Granted: 2001-10-15
Abstract: The present invention provides a pharmaceutical composition comprising a compound admixed with a pharmaceutically acceptable diluent or carrier; wherein the compound has the the formula wherein each of R<sub>1</sub> and R<sub>2</sub> is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl; and wherein the compound is an inhibitor of an enzyme having steroid sulphatase activity (E.C.3.1.6.2); wherein if the sulphamate group on the compound were to be replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at a pH 7.4 and 37°C it would provide a K<sub>m</sub> value of less than 50 µM; and wherein at least one of R<sub>1</sub> and R<sub>2</sub> is H.
Patent JP-3444880-B2 (JP)
IPC: G02B1/10
Filed: 1992-08-28
Granted: 2003-09-08
Abstract: A coating for an article comprising layers of nitrides of certain transition metals to provide an electrically-conductive, light-attenuating, antireflection surface.
Patent JP-3880620-B2 (JP)
IPC: A01P7/04
Filed: 1995-07-06
Granted: 2007-02-14
Abstract: A water dispersible gel comprising:(a) an effective amount of an ionic, water soluble agrochemical;(b) an effective amount of a cross-linked polyacrylic acid;(c) water; and,(d) an amount of a base sufficient to cause a mixture of (a), (b) and (c) to gel.
Patent JP-H0767775-B2 (JP)
IPC: B32B15/06
Filed: 1991-03-07
Abstract: In a method of making a web for manufacturing gaskets, such as vibration and noise damping spacers for vehicle brakes, which gaskets consist of a body of sheet metal, of which at least one side is coated with a rubber layer, a carrier (18), which is in the form of a continuous web and coated on one side with a rubber sheet, is applied to at least one side of a sheet-metal strip (1) provided with a binder. The sheet-metal strip (1) is then passed through a Rotocure<R> machine (9), whereupon the carrier (18) is removed from the sheet-metal strip (1) and the rubber sheet adhering thereto after the curing.
Patent JP-2930595-B2 (JP)
IPC: A61L2/10
Filed: 1988-06-24
Granted: 1999-08-03
Abstract: A method for externally eradicating infectious pathogenic contaminants, such as enveloped viruses, bacteria, trypanosomal and malarial parasites, present in body tissues, such as blood, blood components, semen, skin, and cornea, before the treated body tissues are introduced into, or transplanted onto, the body of a human or an animal. Such method includes the steps of: (1) admixing an effective, non-toxic amount of photoactive compound, which has a selectively for binding to the infectious pathogenic biological contaminants present therein, with the body tissues outside the body to produce resulting body tissues; (2) maintaining the resulting body tissues in a suitable container in which there is no net mass transfer, and (3) irradiating the resulting body tissues in the container for an effective period of time with an effective level of radiation such that the radiation penetrates the resulting body tissues and eradicates the photoactive-compound-bound contaminants present in the resulting body tissues and produces a decontaminated body tissue suitable for introducing into, or transplanting onto, the body of a human or animal.
Patent JP-H07116608-B2 (JP)
IPC: C30B25/02
Filed: 1988-06-17
Abstract: This invention discloses a system for chemically depositing various materials carried by a reactant gas onto substrates for manufacturing semiconductor devices. The system includes special loading and unloading sub-system for placement of substrates to be processed into the system and subsequent extraction without contamination of the system. A special substrate handling sub-system is provided for moving the substrates to and from at least one processing sub-system without physically contacting the planar surfaces of the substrates. The processing sub-system includes a horizontal gas flow reaction chamber having a rotatable susceptor therein for rotating the single substrate supportable thereon about an axis that is normal to the center of the substrate for averaging of the temperature and reactant gas concentration variables. The processing sub-system is separated from the handling sub-system by a special isolation valve and a gas injection device is used to inject the gas into the reaction chamber with a predetermined velocity profile. A special temperature sensing arrangement is provided in the processing sub-system for controlling a radiant heating sub-system which is provided above and below the reaction chamber.
Patent JP-2693643-B2 (JP)
IPC: C12Q1/68
Filed: 1992-10-14
Granted: 1997-12-24
Abstract: Sequence-specific oligonucleotides are provided having substantially pure chiral Sp phosphorothioate, chiral Rp phosphorothioate, chiral Sp alkylphosphonate, chiral Rp alkylphosphonate, chiral Sp phosphoamidate, chiral Rp phosphoamidate, chiral Sp phosphotriester, and chiral Rp phosphotriester linkages. The novel oligonucleotides are prepared via a stereospecific SN2 nucleophilic attack of a phosphodiester, phosphorothioate, phosphoramidate, phosphotriester or alkylphosphonate anion on the 3' position of a xylonucleotide. The reaction proceeds via inversion at the 3' position of the xylo reactant species, resulting in the incorporation of phosphodiester, phosphorothioate, phosphoramidate, phosphotriester or alkylphosphonate linked ribofuranosyl sugar moieties into the oligonucleotide.
Patent JP-2621970-B2 (JP)
IPC: C07K7/06
Filed: 1988-08-24
Granted: 1997-06-18
Abstract: Antide is the decapeptide, N-Ac-D-2-Nal,D-pClPhe, D-3-Pal, Ser,NicLys, D-NicLys, Leu, ILys, Pro, D-Ala,NH2 which is an antagonist of luteinizing hormone releasing hormone (LHRH). This decapeptide, like others of the present invention, has high antiovulatory activity (AOA) and releases negligible histamine. Antide is scheduled for scale-up, safety testing and evaluation in the experimental primate and in clinical medicine. Numerous other peptides having structures related to Antide were prepared and tested. These peptides had variations primarily in positions 5, 6, 7, and 8. Of these, N-Ac-D-2-Nal, D-pClPhe,D-3-Pal,Ser,PicLys,cis-DpzACAla, Leu,ILys,pro,D-Ala-NH2 was one of the most potent and had higher antiovulatory activity than Antide, i.e. 73%/0.25 ug and 100%/0.5 ug vs. 36%/0.5 ug and 100%/1.0 ug. Antide showed significant, (p<0.001) duration of action, when injected at a dose of 10 ug, 44 hours before 50 ng of the agonist, [D-3-Qal6]-LHRH. Antide showed oral AOA at 600 ug (73%) and at 1200 ug (100%) with negligible difference being found between water and corn oil oral formulations.
Patent JP-H0659388-B2 (JP)
IPC: B01D53/34
Filed: 1990-04-30
Abstract: This application relates to a catalyst and a process using this catalyst to convert or destroy organic compounds including organohalogen compounds. A preferred catalyst contains as catalytic components titania, vanadium oxide, tungsten oxide, tin oxide and at least one noble metal selected from the group consisting of platinum, palladium and rhodium, characterized in that the vanadium oxide, tungsten oxide and noble metals are uniformly dispersed on the titania. The process of this invention comprises contacting the gas stream, which contains organohalogen compounds and other organic compounds, at a temperature of about 200 to about 500 DEG C with the catalyst described above in the presence of an oxidizing agent and water. The oxidizing agent can be oxygen or air.
Patent JP-3602530-B2 (JP)
IPC: C12P21/06
Filed: 1992-03-09
Granted: 2004-12-15
Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.\!
Patent JP-3224130-B2 (JP)
IPC: G10L19/02
Filed: 1991-04-12
Granted: 2001-10-29
Abstract: PCT No. PCT/US91/02512 Sec. 371 Date Dec. 11, 1991 Sec. 102(e) Date Dec. 11, 1991 PCT Filed Apr. 12, 1991 PCT Pub. No. WO91/16769 PCT Pub. Date Oct. 31, 1991.The invention relates in general to high-quality low bit-rate digital transform coding and decoding of information corresponding to audio signals such as music signals. More particularly, the invention relates to signal analysis/synthesis in coding and decoding. The invention can optimize the trade off in transform coders between time resolution and frequency resolution by adaptively selecting the transform block length for each sampled audio segment, and/or can optimize coding gain by adaptively selecting the transform and/or by adaptively selecting the analysis window or the analysis/synthesis window pair.
Patent JP-3145712-B2 (JP)
IPC: C08K3/36
Filed: 1995-09-14
Granted: 2001-03-12
Abstract: PCT No. PCT/FR95/01182 Sec. 371 Date May 2, 1997 Sec. 102(e) Date May 2, 1997 PCT Filed Sep. 14, 1995 PCT Pub. No. WO96/08529 PCT Pub. Date Mar. 21, 1996The present invention relates to an aqueous silicone dispersion, capable of being cross-linked into an elastomer by removing water and optionally alcohol and/or carboxylic acid, said dispersion being based on at least one polyorganosiloxane (A) having at least two condensable or hydrolysable ORa groups per molecule wherein Ra=H or alkyl, as well as at least one surficant (B). The technical problem consisting of perfecting a stable dispersion capable of being cross-linked into an elastomer that is highly adhesive on any support and that has suitable and economic mechanical properties is solved since this dispersion includes an amino-functionalised polyorganosiloxane (C) of the DTT(N)(OMe) resin type redistributed with aminoethylaminopropyltrimethoxysilane, optionally at least one hydroxylated and/or alkoxylated silicone resin (D), optionally at least on alkoxysilane (E) donating the -ORa terminals of the polydiorganosiloxane (A), optionally at least on condensation catalyst (F) and optionally at least one optionally siliceous filler (G).
Patent JP-4240237-B2 (JP)
IPC: A61K9/12
Filed: 1995-09-21
Granted: 2009-03-18
Abstract: PCT No. PCT/GB95/02231 Sec. 371 Date Apr. 2, 1997 Sec. 102(e) Date Apr. 2, 1997 PCT Filed Sep. 21, 1995 PCT Pub. No. WO96/10421 PCT Pub. Date Apr. 11, 1996The invention relates to a vaccine composition adapted for mucosal administration, and in particular for intranasal administration, the composition comprising an influenza virus antigen or antigens, such as haemagglutinin and neuraminidase influenza virus antigens, and an effective adjuvant amount of a chitosan. The compositions can be used to immunise a host against infection with influenza, the chitosan serving to enhance the stimulation of a protective IgA mucosal immune response and an IgG systemic immune response.
Patent JP-3392871-B2 (JP)
IPC: G01N33/86
Filed: 1994-09-30
Granted: 2003-03-31
Abstract: The present invention relates to an apparatus for conducting a variety of assays that are responsive to a change in the viscosity of a sample fluid and relates to methods of conducting such assays. In particular, the present invention is related to the use of a cartridge for conducting one or more coagulation assays or, conversely, fibrinolysis assays. The disclosed device enjoys simplicity and is adaptable to the point-of-care clinical diagnostic area, including use in accident sites, emergency rooms, surgery or intensive care units.
Patent JP-3993897-B2 (JP)
IPC: A45B9/02
Filed: 1997-09-09
Granted: 2007-10-17
Abstract: A handle for ski sticks and the like provided with a wrist strap. The wrist strap is attached to the stick handle by a first connecting element fixed at the wrist strap and a second connecting element lodged at the ski's stick handle, which are interlocked. To insure that the connection between the stick handle and the wrist strap is disengaged automatically only in case of danger and no inopportune releasing occurs, a flexible releasing device is installed, which holds one of the connecting elements at the interlocked position and yields only when the wrist strap is pulled in the same direction, a direction with a force component running longitudinally in the stick from its tip toward the handle, so that the second connecting element held together by the releasing device can be disengaged from its interlocked position.
Patent JP-3354944-B2 (JP)
IPC: F01C1/44
Filed: 1997-09-24
Granted: 2002-12-09
Abstract: An oscillating-piston engine comprises a housing in which multiple pistons are each arranged pivotably about a piston axis parallel to a central housing axis and are movable together in a revolution direction about said housing axis. It is proposed to arrange, centrally in said housing, a cam piece which is immovable with respect to said housing, there being configured, on the sides of said pistons facing said cam piece, running surfaces which, as said pistons revolve along an outer contour of said cam piece, are guided in constant contact therewith.
Patent JP-3159263-B2 (JP)
IPC: C07D209/16
Filed: 1991-10-11
Granted: 2001-04-23
Abstract: PCT No. PCT/GB91/01768 Sec. 371 Date Apr. 6, 1993 Sec. 102(e) Date Apr. 6, 1993 PCT Filed Oct. 11, 1991 PCT Pub. No. WO92/06688 PCT Pub. Date Apr. 30, 1992.The present invention provides a new medical use for 3-[2-(dimethylamino)-ethyl]-N-methyl-1H-indole-5-methanesulphonamide and physiologically acceptable salts and solvates thereof in the treatment of tension-type headache and headache associated with substances or their withdrawal.
Patent JP-3103114-B2 (JP)
IPC: A61K31/366
Filed: 1993-03-24
Granted: 2000-10-23
Abstract: The present invention provides novel antiviral compounds, refered to as calanolides, and their derivatives of formulae (I) and (II) which may be isolated from plants of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.
Patent JP-4139867-B2 (JP)
IPC: C12N5/02
Filed: 1994-02-02
Granted: 2008-08-27
Abstract: Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. Also disclosed are DNA sequences encoding methods for the production of the same in appropriate host cells, and stable homogeneous pharmaceutical compositions containing the analogs suitable for use in treatment of gram negative bacterial infection and its sequelae.
Patent JP-3390440-B2 (JP)
IPC: G01D5/38
Filed: 1993-05-04
Granted: 2003-03-24
Abstract: The apparatus disclosed herein employs a grating or scale which concentrates light at a preselected wavelength into the positive and negative first orders while minimizing the zeroth order. The scale is illuminated with monochromatic light of the selected wavelength and a poly-phase periodic detector has its sensing plane spaced from the scale a distance less than   <IMAGE>   where W is the width of the illuminated region of the scale. The period of the poly-phase detector is equal to P/2 so that each detector element or phase responds principally to interference between the positive and negative first orders without requiring magnification or redirection of the diffracted light. Preferably, the distance of the sensing plane from the scale is greater than   <IMAGE>   so that the detector response does not include substantial components from diffraction orders higher than the first.
Patent JP-3672571-B2 (JP)
IPC: A23L1/28
Filed: 1996-12-09
Granted: 2005-07-20
Abstract: PCT No. PCT/GB96/03046 Sec. 371 Date Jun. 12, 1998 Sec. 102(e) Date Jun. 12, 1998 PCT Filed Dec. 9, 1996 PCT Pub. No. WO97/22686 PCT Pub. Date Jun. 26, 1997A human food product comprises a higher ploidy strain of Fungi imperfecti of which each parent has a genetic growth constraint not shared by the other parent. One parent is for example auxotrophic for two compounds selected from histidine, arginine, leucine and adenine and the other for the other two. The nucleic acid content of the strain is preferably less than 2% by weight. The strain may be made by killing a higher ploidy strain of Fungi imperfecti and simultaneously reducing its nucleic acid content to below 2% by weight by treatment with water. The process may include preparing a higher ploidy strain of edible Fusarium by culturing two auxotrophs thereof together in a medium containing nutrients permitting both to grow and then culturing organisms derived from such culture in minimal medium. The invention is applicable to the production of human food by culturing the strain in conditions such that reversion or partial reversion to the haploid form(s) is minimised.
Patent JP-3461836-B2 (JP)
IPC: C08G63/78
Filed: 1996-03-06
Granted: 2003-10-27
Abstract: PCT No. PCT/EP96/00941 Sec. 371 Date Aug. 26, 1997 Sec. 102(e) Date Aug. 26, 1997 PCT Filed Mar. 6, 1996 PCT Pub. No. WO96/28492 PCT Pub. Date Sep. 19, 1996A process for the continuous preparation of thermoplastic polyesters by a) a first step of (trans)esterifying a dicarboxylic acid or its esters or ester-forming derivatives with a molar excess of a dihydroxy compound, b) a second step of precondensing the (trans)esterification product of a), and c) a third step of polycondensing the product of b) comprises carrying out step a) and/or step b) of the process in two or more temperature zones.
Patent JP-3167338-B2 (JP)
IPC: B23K3/06
Filed: 1997-06-30
Granted: 2001-05-21
Abstract: A machine for terminating a computer chip with one or more stripes of a solderable paste, comprising a feed plate wheel defined by an outer marginal edge and having an upper exposed plate surface inclined to the horizontal against which an inventory of 3-dimensional chips is placed for loading, at least one narrow groove formed in the exposed plate surface directed outwardly toward the marginal edge wall and arranged to pass through the inventory and receive therein at least one of the chips in restricted orientation, a transfer cavity defined by enclosed side walls and a floor depending from the groove inboard the outer marginal edge for receipt therein of a chip from the groove in fixed orientation, the outer marginal edge wall having an aperture formed therethrough for transferring the chip from the cavity and, a transport device for urging the chip in a specific fixed orientation from the cavity outward through the aperture in a direction different than the direction from which the chip entered the cavity.
Patent JP-3628709-B2 (JP)
IPC: B01L99/00
Filed: 1997-03-21
Granted: 2005-03-16
Abstract: PCT No. PCT/CH97/00121 Sec. 371 Date Sep. 4, 1998 Sec. 102(e) Date Sep. 4, 1998 PCT Filed Mar. 21, 1997 PCT Pub. No. WO97/35663 PCT Pub. Date Oct. 2, 1997The test kit includes a substrate and, welded or bonded thereto, a plastic sheet having blisters. One of the blisters is shaped as a siphon. The other blisters act as reaction vessels and also serve to receive and store a reagent. The test kit may contain a test strip in one of the blisters. The test kit is particularly suited for carrying out immunological tests, whereby the siphon markedly facilitates the procedure during the washing step.